Laboratory Co. of America Holdings (NYSE:LH – Get Free Report)’s stock price was up 7.6% on Thursday following a stronger than expected earnings report. The company traded as high as $237.53 and last traded at $236.57. Approximately 434,961 shares were traded during mid-day trading, a decline of 34% from the average daily volume of 662,510 shares. The stock had previously closed at $219.90.
The medical research company reported $3.50 EPS for the quarter, topping the consensus estimate of $3.48 by $0.02. Laboratory Co. of America had a net margin of 3.60% and a return on equity of 15.39%. The company had revenue of $3.28 billion for the quarter, compared to analyst estimates of $3.26 billion. During the same period in the previous year, the firm earned $3.38 EPS. The business’s revenue was up 7.4% on a year-over-year basis.
Laboratory Co. of America Dividend Announcement
The company also recently declared a quarterly dividend, which will be paid on Friday, December 13th. Investors of record on Tuesday, November 26th will be issued a $0.72 dividend. This represents a $2.88 dividend on an annualized basis and a dividend yield of 1.26%. The ex-dividend date is Tuesday, November 26th. Laboratory Co. of America’s dividend payout ratio is currently 54.55%.
Wall Street Analyst Weigh In
View Our Latest Stock Analysis on LH
Insider Transactions at Laboratory Co. of America
In other Laboratory Co. of America news, CFO Glenn A. Eisenberg sold 15,000 shares of Laboratory Co. of America stock in a transaction dated Thursday, August 15th. The stock was sold at an average price of $223.99, for a total value of $3,359,850.00. Following the completion of the sale, the chief financial officer now owns 31,289 shares in the company, valued at $7,008,423.11. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. In other Laboratory Co. of America news, CFO Glenn A. Eisenberg sold 15,000 shares of Laboratory Co. of America stock in a transaction on Thursday, August 15th. The shares were sold at an average price of $223.99, for a total value of $3,359,850.00. Following the transaction, the chief financial officer now owns 31,289 shares in the company, valued at $7,008,423.11. This trade represents a 0.00 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, EVP Der Vaart Sandra D. Van sold 2,000 shares of the business’s stock in a transaction on Monday, August 19th. The shares were sold at an average price of $227.05, for a total transaction of $454,100.00. Following the sale, the executive vice president now directly owns 3,670 shares of the company’s stock, valued at $833,273.50. This represents a 0.00 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Insiders have sold 30,679 shares of company stock worth $6,946,306 over the last quarter. 0.85% of the stock is currently owned by insiders.
Hedge Funds Weigh In On Laboratory Co. of America
A number of large investors have recently modified their holdings of the company. Price T Rowe Associates Inc. MD lifted its holdings in shares of Laboratory Co. of America by 2.6% during the 1st quarter. Price T Rowe Associates Inc. MD now owns 114,488 shares of the medical research company’s stock valued at $25,012,000 after acquiring an additional 2,934 shares in the last quarter. Mitsubishi UFJ Asset Management Co. Ltd. boosted its position in shares of Laboratory Co. of America by 17.0% in the first quarter. Mitsubishi UFJ Asset Management Co. Ltd. now owns 101,019 shares of the medical research company’s stock worth $22,069,000 after buying an additional 14,708 shares during the period. SG Americas Securities LLC grew its stake in shares of Laboratory Co. of America by 283.1% in the first quarter. SG Americas Securities LLC now owns 23,217 shares of the medical research company’s stock valued at $5,072,000 after buying an additional 17,156 shares in the last quarter. Duality Advisers LP grew its stake in shares of Laboratory Co. of America by 141.3% in the first quarter. Duality Advisers LP now owns 29,580 shares of the medical research company’s stock valued at $6,462,000 after buying an additional 17,323 shares in the last quarter. Finally, Great Valley Advisor Group Inc. purchased a new stake in shares of Laboratory Co. of America during the 2nd quarter valued at about $473,000. 95.94% of the stock is currently owned by hedge funds and other institutional investors.
Laboratory Co. of America Stock Down 0.6 %
The stock has a market capitalization of $19.20 billion, a price-to-earnings ratio of 43.30, a price-to-earnings-growth ratio of 1.70 and a beta of 1.05. The firm has a 50-day moving average of $222.58 and a 200 day moving average of $212.26. The company has a current ratio of 0.88, a quick ratio of 0.77 and a debt-to-equity ratio of 0.39.
About Laboratory Co. of America
Labcorp Holdings Inc provides laboratory services. It operates through two segments, Diagnostics Laboratories and Biopharma Laboratory Services. The company offers various tests, such as blood chemistry analyses, urinalyses, blood cell counts, thyroid, PAP, hemoglobin A1C and vitamin D, prostate-specific antigens, sexually transmitted diseases, hepatitis C, microbiology cultures and procedures, and alcohol and other substance-abuse tests.
Further Reading
- Five stocks we like better than Laboratory Co. of America
- What Investors Need to Know About Upcoming IPOs
- Texas Roadhouse Stock Steering for New Highs This Year
- Top Stocks Investing in 5G Technology
- Monopar Therapeutics Skyrockets 400% on Licensing Deal
- How to Buy Cheap Stocks Step by Step
- Tractor Supply Stock Pulls Back: A Prime Buying Opportunity
Receive News & Ratings for Laboratory Co. of America Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Laboratory Co. of America and related companies with MarketBeat.com's FREE daily email newsletter.